The Theranostic Efficiency of Tumor-Specific, Ph-Responsive, Peptide-Modified, Liposome-Containing Paclitaxel and Superparamagnetic Iron Oxide Nanoparticles
Xiu-Chai Zheng,Wei Ren,Shuang Zhang,Ting Zhong,Xiao-Chuan Duan,Yi-Fan Yin,Mei-Qi Xu,Yan-Li Hao,Zhan-Tao Li,Hui Li,Man Liu,Zhuo-Yue Li,Xuan Zhang
DOI: https://doi.org/10.2147/ijn.s157082
IF: 7.033
2018-01-01
International Journal of Nanomedicine
Abstract:Background: In the present study, the tumor-specific, pH-responsive peptide H7K(R-2)(2) -modified, theranostic liposome-containing paclitaxel (PTX) and superparamagnetic iron oxide nanoparticles (SPIO NPs), PTX/SPIO-SSL-H(7)k(R-2)(2), was prepared by using H7K(R-2)(2) as the targeting ligand, SPIO NPs as the magnetic resonance imaging (MRI) agent, PTX as antitumor drug. Methods: The PTX/SPIO-SSL-H7K(R-2)(2) was prepared by a thin film hydration method. The characteristics of PTX/SPIO-SSL-H7K(R-2)(2) were evaluated. The targeting effect, MRI, and antitumor activity of PTX/SPIO-SSL-H7K(R-2)(2) were investigated detail in vitro and in vivo in human breast carcinoma MDA-MB-231 cell models. Results: Our results of in vitro flow cytometry, in vivo imaging, and in vivo MR imaging confirmed the pH-responsive characteristic of H7K(R-2)(2) in MDA-MB-231 cell line in vitro and in vivo. The results of in vivo MRI and in vivo antitumor activity confirmed the theranostic effect of PTX/SPIO-SSL-H7K(R-2)(2) in MDA-MB-231 tumor-bearing model. Conclusion: Considering all our in vitro and in vivo results, we conclude that we developed targeting modified theranostic liposome which could achieve both role of antitumor and MRI.